Acticor Biotech: Half-Year Report on the Liquidity Contract With the Brokerage Firm Kepler Cheuvreux
- 103
Regulatory News:
ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company dedicated to the development of innovative treatments for cardiovascular emergencies, including ischemic stroke, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.
Under the liquidity contract entered into between ACTICOR BIOTECH and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023:
- 43,423 shares
- € 382,720.54
- Number of executions on buy side on semester: 631
- Number of executions on sell side on semester: 505
- Traded volume on buy side on semester: 59,726 shares for € 419,225.09
- Traded volume on sell side on semester: 50,122 shares for € 385,042.61
As a reminder:
- the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:
- 33,819 shares
- € 412,635.83
- Number of executions on buy side on semester: 356
- Number of executions on sell side on semester: 414
- Traded volume on buy side on semester: 31,336 shares for € 191,946.13
- Traded volume on sell side on semester: 41,970 shares for € 283,671.24
- the following resources appeared on the liquidity account when the activity started:
- 0 shares
- € 600,000.00
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
About ACTICOR BIOTECH
Acticor Biotech is a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), which is aiming to develop an innovative treatment for cardiovascular emergencies, including ischemic stroke.
The positive results from its Phase 1b/2a study, ACTIMIS, confirmed the safety profile and showed a reduction in mortality and intracerebral hemorrhage in the glenzocimab-treated group in patients with stroke. The efficacy of glenzocimab is now being evaluated in an international Phase 2/3 study, ACTISAVE, which will include 1,000 patients. In July 2022, Acticor Biotech was granted "PRIME" status by the European Medicines Agency (EMA) for glenzocimab in the treatment of stroke. This designation will allow the company to strengthen its interactions and obtain early dialogues with regulatory authorities.
Acticor Biotech is supported by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital, Newton Biocapital, CMS Medical Venture Investment (HK) Limited, A&B (HK) Limited, Anaxago, and the Armesa foundation). Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 – ALACT).
For more information, visit: www.acticor-biotech.com
| Buy Side | Sell Side | ||||||
| Number of executions |
Number of shares |
Traded volume in EUR |
Number of executions |
Number of shares |
Traded volume in EUR |
||
| Total | 631 |
59 726 |
419 225.09 |
505 |
50 122 |
385 042.61 |
|
| 02/01/2023 | 2 |
101 |
717.10 |
3 |
416 |
2 978.56 |
|
| 03/01/2023 | 2 |
35 |
248.50 |
1 |
200 |
1 440.00 |
|
| 04/01/2023 | 4 |
416 |
2 941.12 |
3 |
326 |
2 314.60 |
|
| 05/01/2023 | 1 |
1 |
7.10 |
1 |
1 |
7.10 |
|
| 06/01/2023 | 6 |
410 |
2 878.20 |
1 |
1 |
7.08 |
|
| 09/01/2023 | 3 |
455 |
3 171.35 |
1 |
2 |
14.08 |
|
| 10/01/2023 | 1 |
23 |
162.38 |
7 |
672 |
4 771.20 |
|
| 11/01/2023 | 1 |
1 |
7.12 |
3 |
251 |
1 792.14 |
|
| 12/01/2023 | - |
- |
- |
6 |
300 |
2 166.00 |
|
| 13/01/2023 | - |
- |
- |
8 |
680 |
5 004.80 |
|
| 16/01/2023 | - |
- |
- |
4 |
250 |
1 850.00 |
|
| 17/01/2023 | - |
- |
- |
10 |
830 |
6 225.00 |
|
| 18/01/2023 | 1 |
1 |
7.50 |
7 |
751 |
5 707.60 |
|
| 19/01/2023 | 6 |
294 |
2 202.06 |
- |
- |
- |
|
| 20/01/2023 | 4 |
31 |
229.40 |
- |
- |
- |
|
| 23/01/2023 | 2 |
20 |
148.00 |
1 |
1 |
7.50 |
|
| 24/01/2023 | 4 |
122 |
902.80 |
2 |
9 |
66.96 |
|
| 25/01/2023 | 6 |
135 |
999.00 |
1 |
1 |
7.44 |
|
| 26/01/2023 | 2 |
51 |
374.34 |
2 |
3 |
22.11 |
|
| 27/01/2023 | 4 |
19 |
139.46 |
9 |
648 |
4 872.96 |
|
| 30/01/2023 | - |
- |
- |
9 |
1 634 |
12 467.42 |
|
| 31/01/2023 | 6 |
250 |
1 900.00 |
5 |
753 |
5 820.69 |
|
| 01/02/2023 | - |
- |
- |
18 |
2 963 |
23 704.00 |
|
| 02/02/2023 | - |
- |
- |
13 |
1 461 |
12 111.69 |
|
| 03/02/2023 | 3 |
321 |
2 767.02 |
17 |
2 389 |
20 927.64 |
|
| 06/02/2023 | - |
- |
- |
25 |
2 948 |
27 652.24 |
|
| 07/02/2023 | 2 |
500 |
5 000.00 |
21 |
2 002 |
20 160.14 |
|
| 08/02/2023 | - |
- |
- |
13 |
1 250 |
12 812.50 |
|
| 09/02/2023 | 1 |
80 |
832.00 |
17 |
1 500 |
15 795.00 |
|
| 10/02/2023 | 14 |
1 303 |
13 876.95 |
10 |
1 500 |
16 350.00 |
|
| 13/02/2023 | 14 |
1 014 |
10 555.74 |
3 |
106 |
1 127.84 |
|
| 14/02/2023 | 46 |
4 097 |
39 126.35 |
- |
- |
- |
|
| 15/02/2023 | 5 |
545 |
5 150.25 |
8 |
750 |
7 125.00 |
|
| 16/02/2023 | 2 |
12 |
112.80 |
14 |
2 001 |
19 709.85 |
|
| 17/02/2023 | 9 |
750 |
7 402.50 |
6 |
500 |
4 975.00 |
|
| 20/02/2023 | 4 |
1 000 |
9 650.00 |
- |
- |
- |
|
| 21/02/2023 | - |
- |
- |
3 |
66 |
640.20 |
|
| 22/02/2023 | 7 |
250 |
2 400.00 |
1 |
184 |
1 784.80 |
|
| 23/02/2023 | 1 |
250 |
2 375.00 |
1 |
250 |
2 400.00 |
|
| 24/02/2023 | 2 |
250 |
2 400.00 |
1 |
250 |
2 425.00 |
|
| 27/02/2023 | 12 |
1 812 |
16 724.76 |
5 |
327 |
3 070.53 |
|
| 28/02/2023 | 3 |
676 |
5 948.80 |
2 |
250 |
2 250.00 |
|
| 01/03/2023 | 19 |
1 816 |
15 926.32 |
3 |
250 |
2 200.00 |
|
| 02/03/2023 | 10 |
363 |
3 183.51 |
2 |
251 |
2 208.80 |
|
| 03/03/2023 | 2 |
425 |
3 765.50 |
5 |
752 |
6 820.64 |
|
| 06/03/2023 | 18 |
1 108 |
9 839.04 |
4 |
131 |
1 190.79 |
|
| 07/03/2023 | 13 |
1 173 |
10 040.88 |
2 |
17 |
149.60 |
|
| 08/03/2023 | 9 |
945 |
7 720.65 |
1 |
1 |
8.50 |
|
| 09/03/2023 | 25 |
3 889 |
26 289.64 |
4 |
500 |
3 400.00 |
|
| 10/03/2023 | 1 |
250 |
1 675.00 |
- |
- |
- |
|
| 13/03/2023 | 21 |
2 250 |
14 355.00 |
- |
- |
- |
|
| 14/03/2023 | 3 |
257 |
1 619.10 |
1 |
15 |
96.00 |
|
| 15/03/2023 | 20 |
2 119 |
12 459.72 |
4 |
743 |
4 458.00 |
|
| 16/03/2023 | 11 |
1 355 |
7 791.25 |
5 |
791 |
4 635.26 |
|
| 17/03/2023 | 6 |
645 |
3 637.80 |
6 |
703 |
4 014.13 |
|
| 20/03/2023 | 3 |
518 |
2 869.72 |
2 |
336 |
1 891.68 |
|
| 21/03/2023 | 1 |
250 |
1 425.00 |
4 |
250 |
1 435.00 |
|
| 22/03/2023 | 1 |
1 |
5.70 |
4 |
171 |
991.80 |
|
| 23/03/2023 | - |
- |
- |
9 |
1 256 |
7 661.60 |
|
| 24/03/2023 | 6 |
500 |
3 125.00 |
8 |
1 023 |
6 649.50 |
|
| 27/03/2023 | 1 |
26 |
161.20 |
2 |
500 |
3 165.00 |
|
| 28/03/2023 | 6 |
250 |
1 575.00 |
- |
- |
- |
|
| 29/03/2023 | 3 |
474 |
2 962.50 |
2 |
2 |
12.72 |
|
| 30/03/2023 | 6 |
636 |
3 968.64 |
1 |
1 |
6.32 |
|
| 31/03/2023 | 12 |
1 618 |
9 708.00 |
1 |
1 |
6.30 |
|
| 03/04/2023 | 1 |
4 |
24.00 |
4 |
557 |
3 436.69 |
|
| 04/04/2023 | 4 |
297 |
1 826.55 |
6 |
435 |
2 714.40 |
|
| 05/04/2023 | 4 |
270 |
1 671.30 |
1 |
1 |
6.30 |
|
| 06/04/2023 | 6 |
188 |
1 146.80 |
1 |
1 |
6.16 |
|
| 11/04/2023 | - |
- |
- |
2 |
250 |
1 550.00 |
|
| 12/04/2023 | - |
- |
- |
5 |
250 |
1 565.00 |
|
| 13/04/2023 | 1 |
250 |
1 550.00 |
3 |
140 |
876.40 |
|
| 14/04/2023 | 4 |
201 |
1 226.10 |
2 |
11 |
68.09 |
|
| 17/04/2023 | 3 |
192 |
1 190.40 |
3 |
91 |
569.66 |
|
| 18/04/2023 | 10 |
848 |
5 172.80 |
2 |
21 |
130.20 |
|
| 19/04/2023 | 13 |
1 350 |
7 911.00 |
1 |
4 |
24.40 |
|
| 20/04/2023 | 3 |
237 |
1 374.60 |
- |
- |
- |
|
| 21/04/2023 | 6 |
350 |
2 026.50 |
2 |
200 |
1 160.00 |
|
| 24/04/2023 | 1 |
10 |
57.20 |
4 |
420 |
2 448.60 |
|
| 25/04/2023 | - |
- |
- |
6 |
193 |
1 136.77 |
|
| 26/04/2023 | 5 |
352 |
2 034.56 |
2 |
83 |
481.40 |
|
| 27/04/2023 | 9 |
1 296 |
7 218.72 |
1 |
250 |
1 400.00 |
|
| 28/04/2023 | 3 |
413 |
2 230.20 |
2 |
20 |
108.60 |
|
| 02/05/2023 | 3 |
251 |
1 340.34 |
7 |
182 |
990.08 |
|
| 03/05/2023 | 8 |
1 000 |
5 300.00 |
5 |
164 |
885.60 |
|
| 04/05/2023 | 8 |
357 |
1 881.39 |
- |
- |
- |
|
| 05/05/2023 | - |
- |
- |
6 |
813 |
4 438.98 |
|
| 08/05/2023 | - |
- |
- |
9 |
876 |
5 037.00 |
|
| 09/05/2023 | - |
- |
- |
14 |
1 774 |
10 839.14 |
|
| 10/05/2023 | 5 |
250 |
1 525.00 |
2 |
17 |
103.70 |
|
| 11/05/2023 | 5 |
500 |
3 025.00 |
4 |
443 |
2 706.73 |
|
| 12/05/2023 | 5 |
443 |
2 684.58 |
2 |
64 |
391.68 |
|
| 15/05/2023 | 10 |
558 |
3 353.58 |
2 |
500 |
3 050.00 |
|
| 16/05/2023 | 7 |
748 |
4 510.44 |
3 |
738 |
4 523.94 |
|
| 17/05/2023 | - |
- |
- |
3 |
153 |
948.60 |
|
| 18/05/2023 | 4 |
636 |
3 828.72 |
- |
- |
- |
|
| 19/05/2023 | 5 |
287 |
1 750.70 |
- |
- |
- |
|
| 22/05/2023 | 9 |
927 |
5 580.54 |
- |
- |
- |
|
| 23/05/2023 | 5 |
543 |
3 198.27 |
1 |
1 |
6.06 |
|
| 24/05/2023 | 4 |
250 |
1 450.00 |
2 |
499 |
2 969.05 |
|
| 25/05/2023 | 5 |
1 000 |
5 730.00 |
4 |
201 |
1 179.87 |
|
| 26/05/2023 | 4 |
99 |
564.30 |
3 |
161 |
924.14 |
|
| 29/05/2023 | 3 |
152 |
866.40 |
2 |
59 |
338.66 |
|
| 30/05/2023 | 6 |
327 |
1 863.90 |
3 |
250 |
1 435.00 |
|
| 31/05/2023 | 7 |
1 173 |
6 580.53 |
3 |
450 |
2 596.50 |
|
| 01/06/2023 | - |
- |
- |
1 |
1 |
5.60 |
|
| 02/06/2023 | - |
- |
- |
5 |
749 |
4 261.81 |
|
| 05/06/2023 | 2 |
196 |
1 117.20 |
4 |
200 |
1 144.00 |
|
| 06/06/2023 | 7 |
760 |
4 301.60 |
2 |
171 |
981.54 |
|
| 07/06/2023 | 2 |
254 |
1 422.40 |
1 |
24 |
136.80 |
|
| 08/06/2023 | 6 |
490 |
2 753.80 |
3 |
245 |
1 396.50 |
|
| 09/06/2023 | 2 |
250 |
1 400.00 |
- |
- |
- |
|
| 12/06/2023 | 9 |
1 363 |
7 169.38 |
2 |
450 |
2 403.00 |
|
| 13/06/2023 | 6 |
1 250 |
6 425.00 |
3 |
59 |
307.98 |
|
| 14/06/2023 | 4 |
250 |
1 275.00 |
- |
- |
- |
|
| 15/06/2023 | 3 |
251 |
1 280.10 |
1 |
1 |
5.14 |
|
| 16/06/2023 | 3 |
251 |
1 280.10 |
8 |
858 |
4 504.50 |
|
| 19/06/2023 | 1 |
20 |
108.00 |
3 |
384 |
2 112.00 |
|
| 20/06/2023 | 5 |
222 |
1 198.80 |
1 |
1 |
5.42 |
|
| 21/06/2023 | 4 |
309 |
1 650.06 |
3 |
35 |
191.45 |
|
| 22/06/2023 | 3 |
425 |
2 278.00 |
3 |
52 |
282.88 |
|
| 23/06/2023 | 5 |
188 |
985.12 |
3 |
56 |
302.40 |
|
| 26/06/2023 | 3 |
138 |
717.60 |
- |
- |
- |
|
| 27/06/2023 | 2 |
255 |
1 326.00 |
3 |
250 |
1 325.00 |
|
| 28/06/2023 | 5 |
251 |
1 330.30 |
2 |
2 |
10.72 |
|
| 29/06/2023 | 2 |
250 |
1 325.00 |
3 |
192 |
1 052.16 |
|
| 30/06/2023 | 4 |
501 |
2 725.44 |
- |
- |
- |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20230707490254/en/
